Abstract
Adzymes are ‘addressable enzymes’ containing an address domain that binds to a target molecule, and a catalytic domain that degrades or modifies the target. Adzymes are principally designed for the catalytic degradation of bioactive polypeptides, for example, inflammatory mediators. A well-characterised, functional example of an adzyme contains human mesotrypsin as the catalytic domain in fusion with a TNF-α binding protein. Adzymes represent a new generation of protein therapeutics with significant untapped potential, which warrants additional studies to demonstrate in vivo feasibility.
Disclosure
M Sahin-Tóth has received a past grant from Compound Therapeutics to generate mesotrypsin mutants.
Patent Details
Title Adzymes and uses thereof
Assignee Compound Therapeutics, Inc.
Inventors Afeyan NB, Lee FD, Das Gupta R, Baynes B, Camphausen R
Priority date 02/03/2004
Filing date 02/03/2005
Publication date 15/09/2005
Publication no. WO2005085430